gammaCore Sapphire

Overview

gammaCore Sapphire is the only FDA-cleared non-invasive vagus nerve stimulation (nVNS) device in the consumer market — manufactured by electroCore (Rockaway NJ, founded 2005), carrying a series of FDA 510(k) clearances for migraine (acute and preventive) and cluster headache (acute and preventive) — most recently extended, via K211856 (September 2021), to paroxysmal hemicrania and hemicrania continua. The structural positioning is fundamentally different from every other consumer VNS device in this category: gammaCore is prescription-grade clinical neurostimulation, not wellness-tier biohacker positioning.

The structural credibility differentiator is regulatory. gammaCore carries actual FDA 510(k) clearance for two specific neurological indications — migraine and cluster headache. The clinical evidence base includes 15+ randomized controlled trials supporting these indications. By contrast, every other consumer VNS device in the category (Pulsetto, Truvaga, Nurosym, Apollo Neuro) carries general-wellness or CE-mark only positioning — they are not FDA-cleared for any neurological indication.

The structural editorial caveat: gammaCore is not marketed for wellness applications. The device is prescription-only, requires a neurology or headache specialist for access, costs ~$598/month cash price (highest in the consumer category), and has limited insurance coverage despite FDA clearance. For wellness-focused biohackers seeking VNS for stress, sleep, anxiety, or HRV optimization, gammaCore is the wrong tool — Truvaga or Pulsetto are structurally better. For migraine or cluster headache patients seeking the most clinically-validated non-invasive VNS option, gammaCore is the only meaningful choice.

What We Measured

Note: This review is based on gammaCore Sapphire’s published 510(k) K211856 clearance documentation, randomized controlled trial publications, electroCore corporate disclosures, prescription-pathway documentation, and aggregated patient reports from migraine / cluster headache communities. Hands-on testing of the prescription pathway and device experience is pending.

The FDA 510(k) clearance

This is the central structural differentiator. gammaCore’s clearance history runs across a series of FDA 510(k)s: acute cluster headache (2017), acute migraine (2018), cluster-headache prevention (2018), migraine prevention (2020), adolescent migraine (2021), and — most recently — K211856 (September 2021) for paroxysmal hemicrania and hemicrania continua. Note that K211856 is the latest clearance, not the migraine/cluster-headache one; those indications come from the earlier clearances listed above.

For comparison:

• Pulsetto: general-wellness exemption only (not FDA-cleared)
• Truvaga: general-wellness exemption only (uses gammaCore technology platform but Truvaga itself is not cleared)
• Nurosym: CE-mark only (UK / EU), no FDA clearance
• Apollo Neuro: general-wellness only (not technically VNS — autonomic-tone vibration therapy)
• gammaCore Sapphire: the only FDA-cleared nVNS — 510(k) clearances for migraine + cluster headache (acute and preventive), with K211856 the most recent (paroxysmal hemicrania / hemicrania continua)

For users prioritizing regulatory clearance as a structural credibility signal, gammaCore is structurally unmatched. No other consumer-accessible VNS device carries comparable regulatory positioning.

The clinical evidence base

The gammaCore product line is supported by 15+ randomized controlled trials across migraine and cluster headache indications. Key publications include:

• PRESTO trial (acute treatment of migraine): RCT supporting acute migraine indication
• PREMIUM trials (prevention of migraine): RCTs supporting prophylactic indication
• ACT-1, ACT-2 trials (cluster headache): RCTs supporting cluster headache indication
• Real-world evidence registries: post-market patient outcomes data

For comparison, no other consumer VNS device has comparable RCT depth. Nurosym claims 50+ trials but most are smaller pilot studies; the gammaCore RCT portfolio is materially larger and more rigorously published.

For migraine or cluster headache patients evaluating evidence quality, gammaCore is structurally the most-validated non-invasive VNS option in the consumer market.

The 2-minute stimulation protocol

gammaCore Sapphire uses 2-minute cervical (neck) stimulation sessions — among the shortest in the consumer VNS category. Compared to Nurosym’s 30–60 minute auricular (ear-clip) sessions, gammaCore’s protocol is meaningfully more workflow-friendly.

For acute migraine or cluster-headache treatment (where rapid intervention timing matters), the 2-minute protocol is structurally better than 30+ minute alternatives. For wellness applications (HRV optimization, stress reduction), longer protocols may deliver more cumulative dose — but this isn’t gammaCore’s marketed use case.

The prescription-pathway and refill-card system

gammaCore operates under a prescription + refill-card model. Users obtain initial prescription from neurology / headache specialist, then receive refill cards monthly. Each card unlocks a fixed number of stimulation sessions on the Sapphire device.

The refill economics:

• Cash price: ~$598/month
• Typical insurance: limited coverage despite FDA clearance
• VA / military supply: covered for eligible patients (Tac-Stim variant)

For most consumers, the cash price is prohibitive. For VA-eligible patients or those with strong insurance coverage, the cost barrier is materially lower. This structural pricing reality is the central editorial constraint — gammaCore is structurally the right tool for clinically-validated migraine + cluster headache treatment, but the access pathway limits its consumer-market reach.

The electroCore / Truvaga relationship

This is meaningful editorial context. Truvaga is electroCore’s wellness-positioned brand using the gammaCore technology platform. Truvaga is NOT FDA-cleared — it’s positioned for general wellness (stress, sleep, focus) at consumer pricing without prescription requirement.

The platform overlap:

• Same underlying nVNS technology (cervical stimulation, similar waveforms)
• Different regulatory positioning (gammaCore: FDA-cleared / Truvaga: general wellness)
• Different access pathway (gammaCore: prescription-only / Truvaga: direct consumer purchase)
• Different pricing (gammaCore: ~$598/month / Truvaga: ~$499 one-time)

For users who want gammaCore’s underlying technology without the prescription requirement, Truvaga is structurally the consumer-accessible alternative — though without the FDA clearance and clinical evidence base.

3-Year Cost of Ownership

Use case	Annual cost	3-year total
Cash-pay monthly refills	~$7,176	~$21,528
Insurance copay (typical)	~$2,000–$3,500	~$6,000–$10,500
VA / military supply	$0 (covered)	$0

Compare: Pulsetto ($269 one-time, no refills), Truvaga 350 ($499 one-time, fixed-session model), Truvaga Plus ($799 one-time, unlimited), Nurosym (~$729 one-time + replacement electrodes).

gammaCore is structurally the most expensive consumer VNS device by orders of magnitude. The cost premium is justified for users with FDA-cleared indications (migraine, cluster headache) and either insurance coverage or VA eligibility. For cash-pay wellness applications, the math doesn’t pencil out.

Regulatory Status

FDA 510(k) Cleared. The only FDA-cleared non-invasive VNS device in the consumer market. Clearances cover migraine (acute, prevention) and cluster headache (acute, prevention); the most recent — K211856 (September 2021) — adds paroxysmal hemicrania and hemicrania continua.

Verify on the FDA database — gammaCore Sapphire entry links directly to accessdata.fda.gov K211856 record.

When gammaCore Makes Sense — And When It Doesn’t

Strong fit:

• You have diagnosed migraine or cluster headache and want the most clinically-validated non-invasive VNS option
• You have insurance coverage or are VA-eligible — the cost barrier is materially lower
• You value FDA 510(k) clearance as a structural credibility signal
• You want 2-minute acute-treatment protocol for rapid intervention timing
• You’re a neurology / headache clinic patient following physician-recommended treatment pathway

Weaker fit:

• You want wellness / stress / HRV / sleep applications — gammaCore is not marketed for these uses
• You’re cash-pay without insurance — $598/month is prohibitive for most consumers
• You want direct consumer purchase — gammaCore requires prescription
• You want 30+ minute deeper-dose VNS protocols — Nurosym is structurally better
• You’re a biohacker exploring VNS for general optimization — Pulsetto, Truvaga, or Nurosym are structurally better matches

Verdict: Recommended

gammaCore Sapphire earns a recommended verdict on the strength of its category-unique FDA 510(k) clearances (the only consumer-accessible non-invasive VNS device with FDA clearance — covering migraine and cluster headache, with K211856 the most recent addition), 15+ randomized controlled trial clinical evidence base supporting migraine and cluster headache indications, 2-minute stimulation protocol enabling rapid acute-treatment workflow, electroCore’s 20+ year multi-decade neurostimulation research portfolio, and VA / military supply availability providing access pathway for eligible patients.

For diagnosed migraine or cluster headache patients with insurance coverage or VA eligibility, gammaCore is structurally the leading non-invasive VNS choice. The combination of FDA clearance + RCT evidence base + clinical-grade positioning is unmatched.

For wellness-focused biohackers, cash-pay consumers, or HRV / stress / sleep optimization use cases, gammaCore is the wrong tool — the prescription requirement, $598/month cash pricing, and migraine-only marketed indication make it inaccessible and inappropriate. Truvaga (gammaCore technology, wellness-positioned), Pulsetto (cheapest consumer entry), or Nurosym (UK clinical-tier with longer-dose protocols) are structurally better for non-headache use cases.

The editorial framing: gammaCore is the medical-grade endpoint of the consumer VNS spectrum. For clinically-indicated patients, it’s the right tool; for wellness consumers, the spectrum’s other end (Truvaga, Pulsetto) is structurally better. Buyers should match positioning to actual use case.

Sources

• FDA 510(k) database — K211856 (gammaCore Sapphire; the September 2021 clearance for paroxysmal hemicrania and hemicrania continua).
• electroCore — FDA clearance for the acute treatment of episodic cluster headache (the first nVNS clearance, 2017).
• electroCore — FDA clearance for the acute treatment of migraine (January 2018).
• electroCore — FDA clearance for the preventive treatment of cluster headache (November 2018).
• electroCore — 510(k) clearance K211856 for paroxysmal hemicrania and hemicrania continua (September 2021).

Changelog

• 2026-05-06: Initial review published based on gammaCore Sapphire’s FDA 510(k) K211856 clearance documentation, RCT publications (PRESTO, PREMIUM, ACT-1/2), electroCore corporate disclosures, and aggregated patient-report data.
• 2026-06-30: Corrected the K211856 attribution — K211856 (September 2021) is gammaCore’s clearance for paroxysmal hemicrania and hemicrania continua, not migraine + cluster headache (those come from earlier 510(k)s: cluster-headache acute 2017, migraine acute 2018, cluster prevention 2018, migraine prevention 2020). Added primary sources. gammaCore remains the only FDA-cleared consumer nVNS; the recommendation is unchanged.